LGVN
Price
$0.80
Change
+$0.01 (+1.27%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
16.71M
RXRX
Price
$4.67
Change
+$0.04 (+0.86%)
Updated
Sep 26, 03:42 PM (EDT)
Capitalization
2.02B
40 days until earnings call
Interact to see
Advertisement

LGVN vs RXRX

Header iconLGVN vs RXRX Comparison
Open Charts LGVN vs RXRXBanner chart's image
Longeveron
Price$0.80
Change+$0.01 (+1.27%)
Volume$1K
Capitalization16.71M
Recursion Pharmaceuticals
Price$4.67
Change+$0.04 (+0.86%)
Volume$4.33K
Capitalization2.02B
LGVN vs RXRX Comparison Chart in %
Loading...
LGVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LGVN vs. RXRX commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LGVN is a StrongBuy and RXRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (LGVN: $0.79 vs. RXRX: $4.63)
Brand notoriety: LGVN and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LGVN: 21% vs. RXRX: 214%
Market capitalization -- LGVN: $16.71M vs. RXRX: $2.02B
LGVN [@Biotechnology] is valued at $16.71M. RXRX’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LGVN’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • LGVN’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LGVN is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LGVN’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • LGVN’s TA Score: 5 bullish, 2 bearish.
  • RXRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, LGVN is a better buy in the short-term than RXRX.

Price Growth

LGVN (@Biotechnology) experienced а +3.06% price change this week, while RXRX (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +52.01%.

Reported Earning Dates

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.02B) has a higher market cap than LGVN($16.7M). RXRX YTD gains are higher at: -31.509 vs. LGVN (-54.127). LGVN has higher annual earnings (EBITDA): -18.35M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. LGVN (10.3M). LGVN has less debt than RXRX: LGVN (1.14M) vs RXRX (88.1M). RXRX has higher revenues than LGVN: RXRX (64.5M) vs LGVN (2.07M).
LGVNRXRXLGVN / RXRX
Capitalization16.7M2.02B1%
EBITDA-18.35M-583.64M3%
Gain YTD-54.127-31.509172%
P/E Ratio3.17N/A-
Revenue2.07M64.5M3%
Total Cash10.3M525M2%
Total Debt1.14M88.1M1%
TECHNICAL ANALYSIS
Technical Analysis
LGVNRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
LGVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDIKX50.96N/A
N/A
Fidelity Diversified International K
CDOYX42.56N/A
N/A
Columbia Dividend Opportunity Inst3
RIEIX13.11N/A
N/A
RBC International Equity I
SILVX18.42N/A
N/A
SGI US Large Cap Equity I
BAHAX17.98N/A
N/A
Brown Advisory WMC Strat Eurp Eq Adv